Why Merck (MRK) is a Top Momentum Stock for the Long-Term
https://www.zacks.com/stock/news/2248395/why-merck-mrk-is-a-top-momentum-stock-for-the-long-term?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_momentum_score-2248395
Apr 01, 2024 - The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
0
Genprex (GNPX) Expands SCLC Study of Key Candidate, Stock Up
https://www.zacks.com/stock/news/2250526/genprex-gnpx-expands-sclc-study-of-key-candidate-stock-up?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2250526
Apr 04, 2024 - Genprex (GNPX) gains 9.5% after expanding clinical study sites in the United States for the early to mid-stage study of lead candidate, Reqorsa, to treat lung cancer patients.
0
Merck (MRK) Begins Phase II/II Ovarian Cancer Study on ADC Drug (Revised)
https://www.zacks.com/stock/news/2252285/merck-mrk-begins-phase-ii-ii-ovarian-cancer-study-on-adc-drug-revised?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2252285
Apr 08, 2024 - Merck's (MRK) phase II/III study called REJOICE-Ovarian01 study will evaluate the efficacy of raludotatug deruxtecan in patients with platinum-resistant ovarian cancer.
0
Top Analyst Reports for Microsoft, Novo Nordisk & United Parcel
https://www.zacks.com/commentary/2255375/top-analyst-reports-for-microsoft-novo-nordisk-united-parcel?cid=CS-ZC-FT-research_daily-2255375
Apr 15, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Novo Nordisk A/S (NVO) and United Parcel Service, Inc. (UPS).
0
Merck (MRK) Advances While Market Declines: Some Information for Investors
https://www.zacks.com/stock/news/2257229/merck-mrk-advances-while-market-declines-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2257229
Apr 17, 2024 - In the most recent trading session, Merck (MRK) closed at $125.37, indicating a +0.25% shift from the previous trading day.
0
Exelixis (EXEL) Collaborates With Arcus for Kidney Cancer Study
https://www.zacks.com/stock/news/2193811/exelixis-exel-collaborates-with-arcus-for-kidney-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2193811
Dec 05, 2023 - Exelixis (EXEL) partners with Arcus Biosciences for a phase Ib/II study to evaluate zanzalintinib in combination with AB521 for ccRCC.
0
Merck's (MRK) Keytruda-Lynparza Combo Fails Lung Cancer Study
https://www.zacks.com/stock/news/2195640/merck-s-mrk-keytruda-lynparza-combo-fails-lung-cancer-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2195640
Dec 08, 2023 - After a late-stage study fails to show any improvement in its primary endpoints, Merck (MRK) decides to stop evaluating the Keytruda-Lynparza combination in metastatic squamous NSCLC.
0
Company News for Dec 8, 2023
https://www.zacks.com/stock/news/2195478/company-news-for-dec-8-2023?cid=CS-ZC-FT-corporate_summary-2195478
Dec 08, 2023 - Companies In The Article Are: CIEN,MRK,VRNT,OXM
0
Merck (MRK) Gets EU Nod for Expanded Use in Gastric Cancer
https://www.zacks.com/stock/news/2200047/merck-mrk-gets-eu-nod-for-expanded-use-in-gastric-cancer?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2200047
Dec 19, 2023 - Following these approvals, Merck's (MRK) Keytruda is approved for seven gastrointestinal cancers in the European Union. Overall, the drug is approved for 26 indications in the region.
0
FDA Accepts Merck's (MRK) BLA for 21-Valent Pneumococcal Jab
https://www.zacks.com/stock/news/2200645/fda-accepts-merck-s-mrk-bla-for-21-valent-pneumococcal-jab?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2200645
Dec 20, 2023 - The FDA grants priority review to Merck's (MRK) filing seeking approval for its 21-valent pneumococcal conjugate vaccine in adults. A final decision is expected in June 2024.
0